New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2013
10:15 EDTGHL, AEO, TUP, HMY, CRH, VELT, POT, CHK, SNY, DKS, MOS, AGUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Agrium (AGU) downgraded to Neutral from Overweight at HSBC... Chesapeake (CHK) downgraded to Neutral from Positive at Susquehanna... Harmony Gold (HMY) downgraded to Sell from Neutral at UBS... Mosaic (MOS) downgraded to Underweight from Neutral at HSBC... Potash (POT) downgraded to Underweight from Overweight at HSBC... Tupperware Brands (TUP) downgraded to Market Perform from Outperform at BMO Capital... Dick's Sporting (DKS) downgraded to In-Line from Outperform at Imperial Capital... Velti (VELT) downgraded at RBC Capital... American Eagle (AEO) downgraded to Neutral from Overweight at Piper Jaffray... Sanofi (SNY) downgraded to Market Perform from Outperform at Cowen... CRH Plc. (CRH) downgraded to Outperform from Strong Buy at Raymond James... Greenhill & Co. (GHL) downgraded to Market Perform from Outperform at JMP Securities.
News For AGU;CHK;HMY;MOS;POT;TUP;DKS;VELT;AEO;SNY;CRH;GHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 15, 2015
16:35 EDTCHKIcahn Associates gives quarterly update on stakes
NEW STAKES: None. INCREASED STAKES: Manitowoc (MTW), Voltari (VLTC), Federal-Mogul Holdings (FDML), and Chesapeake Energy (CHK). DECREASED STAKES: None. LIQUIDATED STAKES: None.
10:45 EDTCHKStocks with call strike movement; CHK RIG
Chesapeake (CHK) October 17 call option implied volatility increased 2% to 45, Transocean (RIG) August 21 call option implied volatility increased 4% to 42 according to IVolatility.
10:29 EDTSNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
08:24 EDTAEOAmerican Eagle, Express should be bought ahead of results, says BMO Capital
Subscribe for More Information
07:41 EDTAEOAmerican Eagle volatility elevated into Q1 and outlook
Subscribe for More Information
May 14, 2015
16:14 EDTMOSMosaic up 1% after announcing new $1.5B buyback plan, dividend increase
Subscribe for More Information
16:12 EDTMOSMosaic announces new $1.5B share buyback plan, raises dividend to 27.5c
Subscribe for More Information
16:11 EDTMOSMosaic increases dividend to 27.5c from 25c
16:11 EDTMOSMosaic announces New $1.5B share repurchase authorization
13:28 EDTCHKIncreasing equity options volume
Increasing equity options volume: FCX UPS KSS CHK CSCO AVP YOKU CALM KORS
07:28 EDTDKSDick's Sporting volatility flat into Q1 and outlook
Subscribe for More Information
May 13, 2015
17:27 EDTMOSMosaic announces Joc O'Rourke to succeed Jim Prokopanko as CEO
Subscribe for More Information
11:28 EDTCHKStocks with call strike movement; TWTR JCP
Subscribe for More Information
10:01 EDTAEO, DKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:28 EDTDKSDick's Sporting view changed to Positive from Mixed at OTR Global
OTR Global changed its view on Dick's Sporting Goods to Positive from Mixed due to a recovery in the demand for golf, lower clearance inventory, increasing transaction counts, and a favorable initial response to Calia.
07:56 EDTDKSDick's Sporting should report solid Q1 results, says UBS
Subscribe for More Information
07:31 EDTSNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
06:08 EDTAEOAmerican Eagle upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
May 12, 2015
08:04 EDTCHKCitigroup to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use